Treatment Response Biomarkers: Working Toward Personalized Radiotherapy for Lung Cancer

被引：2
作者：
Horne, Ashley [1 ,2 ]
Harada, Ken [3 ]
Brown, Katherine D. [1 ,4 ]
Chua, Kevin Lee Min [5 ]
MCdonald, Fiona [6 ]
Price, Gareth [1 ]
Putora, Paul Martin [7 ,8 ]
Rothwell, Dominic G. [9 ]
Faivre-Finn, Corinne [1 ,2 ]
机构：
[1] Univ Manchester, Div Canc Sci, Paterson Bldg,Wilmslow Rd, Manchester M20 4BX, England
[2] Christie NHS Fdn Trust, Dept Radiat Oncol, Manchester, England
[3] Showa Univ Northern Yokohama Hosp, Dept Radiat Oncol, Yokohama, Kanagawa, Japan
[4] Christie Hosp NHS Fdn Trust, Dept Res & Innovat, Manchester, England
[5] Natl Canc Ctr, Div Radiat Oncol, Singapore, Singapore
[6] Royal Marsden Hosp, London, England
[7] Kantonsspital St Gallen, Dept Radiat Oncol, St Gallen, Switzerland
[8] Univ Bern, Dept Radiat Oncol, Inselspital, Bern, Switzerland
[9] Univ Manchester, CR UK Natl Biomarker Ctr, Manchester, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 08期
基金：
英国医学研究理事会;
关键词：
Lung cancer; Personalised medicine; Radio-; therapy; Treatment response biomarkers; ADAPTIVE RADIOTHERAPY; PROGNOSTIC VALUE; TUMOR-CELLS; PHASE-II; RADIOSENSITIVITY; DURVALUMAB; RADIOMICS; DISEASE; PET/CT; NSCLC;
D O I：
10.1016/j.jtho.2024.04.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Owing to major advances in the field of radiation oncology, patients with lung cancer can now receive technically individualized radiotherapy treatments. Nevertheless, in the era of precision oncology, radiotherapy-based treatment selection needs to be improved as many patients do not benefit or are not offered optimum therapies. Cost-effective robust biomarkers can address this knowledge gap and lead to individuals being offered more bespoke treatments leading to improved outcome. This narrative review discusses some of the current achievements and challenges in the realization of personalized radiotherapy delivery in patients with lung cancer. (c) 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).
引用
收藏
页码：1164 / 1185
页数：22
相关论文
共 77 条
  • [21] Multitask Learning Radiomics on Longitudinal Imaging to Predict Survival Outcomes following Risk-Adaptive Chemoradiation for Non-Small Cell Lung Cancer
    Forouzannezhad, Parisa
    Maes, Dominic
    Hippe, Daniel S.
    Thammasorn, Phawis
    Iranzad, Reza
    Han, Jie
    Duan, Chunyan
    Liu, Xiao
    Wang, Shouyi
    Chaovalitwongse, W. Art
    Zeng, Jing
    Bowen, Stephen R.
    [J]. CANCERS, 2022, 14 (05)
  • [22] The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers
    Friedenson, Bernard
    [J]. BMC CANCER, 2007, 7
  • [23] Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
    Gandara, David R.
    Paul, Sarah M.
    Kowanetz, Marcin
    Schleifman, Erica
    Zou, Wei
    Li, Yan
    Rittmeyer, Achim
    Fehrenbacher, Louis
    Otto, Geoff
    Malboeuf, Christine
    Lieber, Daniel S.
    Lipson, Doron
    Silterra, Jacob
    Amler, Lukas
    Riehl, Todd
    Cummings, Craig A.
    Hegde, Priti S.
    Sandler, Alan
    Ballinger, Marcus
    Fabrizio, David
    Mok, Tony
    Shames, David S.
    [J]. NATURE MEDICINE, 2018, 24 (09) : 1441 - +
  • [24] Analysis of circulating tumor cells from lung cancer patients with multiple biomarkers using high-performance size-based microfluidic chip
    Gao, Wanlei
    Yuan, Haojun
    Jing, Fengxiang
    Wu, Shan
    Zhou, Hongbo
    Mao, Hongju
    Jin, Qinghui
    Zhao, Jianlong
    Cong, Hui
    Jia, Chunping
    [J]. ONCOTARGET, 2017, 8 (08) : 12917 - 12928
  • [25] Guangdong Association of Clinical Trials, MRD guiding treatment after Almonertinib induction therapy for EGFRmp Stage III NSCLC in the MDT diagnostic model. (APPROACH)
  • [26] Guidelines for the use of biomarkers: Principles, processes and practical considerations
    Horvath, Andrea R.
    Kis, Erika
    Dobos, Eva
    [J]. SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2010, 70 : 109 - 116
  • [27] DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
    Huang, Rui-Xue
    Zhou, Ping-Kun
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
  • [28] IRCCS Policlinico S. Matteo, Blue Sky Radiomics: an observational study on computed tomography as an image-based predictive marker of response to chemoradiation followed by durvalumab in Stage III unresectable non-small cell lung cancer (NSCLC)
  • [29] Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
    Jazieh, Khalid
    Khorrami, Mohammadhadi
    Saad, Anas
    Gad, Mohamed
    Gupta, Amit
    Patil, Pradnya
    Viswanathan, Vidya Sankar
    Rajiah, Prabhakar
    Nock, Charles J.
    Gilkey, Michael
    Fu, Pingfu
    Pennell, Nathan A.
    Madabhushi, Anant
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
  • [30] A New Frontier for Cancer Genetics: Identification of Germline-Somatic Associations
    Kar, Siddhartha P.
    [J]. CANCER RESEARCH, 2023, 83 (08) : 1165 - 1166
12345678